Pfizer has a 6.8% yield at a time when the market's yield is roughly 1%: Is there something wrong?

Income seekers shouldn't give up on the stock yet.

Pfizer carries one of Big Pharma's fattest yields while Merck burns cash on deals to secure its next growth era. Which ...

You may also know that Pfizer's top-selling drugs, like the blood thinner Eliquis and cancer treatments Ibrance and Xtandi, ...

Pfizer reported second-quarter adjusted earnings per share of $0.77, beating Wall Street's consensus estimate of $0.68, and ...

Pfizer is dealing with headwinds right now, but they aren't unusual headwinds in the pharmaceutical sector. The company is taking aggressive actions to get back on track and recently stated it plans ...

Income investors usually don't mind too much if a stock doesn't deliver tremendous gains, as long as it keeps the dividends flowing. They typically don't like it when a stock tumbles, though, as ...

The stock's yield is more than six times the S&P 500 average.

Pfizer is a highly respected drug company facing normal industry headwinds.

Dividend stocks can be a great way to generate passive income. Investors must ensure that companies are generating sufficient free cash flow and earnings to cover their dividends, ideally with the ...

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...